![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer and BioNTech Report Positive Results from COVID-19 Vaccine Trial
Pfizer and BioNTech Report Positive Results from COVID-19 Vaccine Trial
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
July 2, 2020
Pfizer and BioNTech have announced positive early results from a phase 1 /2 study of their lead COVID-19 vaccine candidate in the U.S.
All 24 volunteers who received either two 10 mcg or 30 mcg doses of the messenger RNA-based vaccine produced neutralizing antibodies up to 2.8 times more than those seen in recovered COVID-19 patients, and no serious adverse events were reported.
The companies expect to begin a phase 2b/3 trial of the vaccine later this month.
Upcoming Events
-
21Oct